CA2426492A1 - A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease - Google Patents

A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease Download PDF

Info

Publication number
CA2426492A1
CA2426492A1 CA002426492A CA2426492A CA2426492A1 CA 2426492 A1 CA2426492 A1 CA 2426492A1 CA 002426492 A CA002426492 A CA 002426492A CA 2426492 A CA2426492 A CA 2426492A CA 2426492 A1 CA2426492 A1 CA 2426492A1
Authority
CA
Canada
Prior art keywords
nmda
antagonist
treatment
alzheimer
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002426492A
Other languages
French (fr)
Other versions
CA2426492C (en
Inventor
Lars Lykke Thomsen
Anders Gersel Pedersen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
H Lundbeck AS
Original Assignee
H Lundbeck AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=28051666&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2426492(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck AS filed Critical H Lundbeck AS
Priority to CA002558708A priority Critical patent/CA2558708A1/en
Publication of CA2426492A1 publication Critical patent/CA2426492A1/en
Application granted granted Critical
Publication of CA2426492C publication Critical patent/CA2426492C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Provided herein is a pharmaceutical composition comprising: (a) an effective amount of one or more of acetylcholinesterase inhibitors) or a pharmaceutically effective salt thereof; and (b) an effective amount of one or more NMDA-antagonist(s). Also provided is the use of the above composition for the manufacture of a medicament for the treatment of mild cognitive impairment or dementia.
CA002426492A 2002-05-31 2003-05-08 A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease Expired - Fee Related CA2426492C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA002558708A CA2558708A1 (en) 2002-05-31 2003-05-08 A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200200844 2002-05-31
DKPA200200844 2002-05-31

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA002558708A Division CA2558708A1 (en) 2002-05-31 2003-05-08 A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease

Publications (2)

Publication Number Publication Date
CA2426492A1 true CA2426492A1 (en) 2003-09-16
CA2426492C CA2426492C (en) 2006-10-03

Family

ID=28051666

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002426492A Expired - Fee Related CA2426492C (en) 2002-05-31 2003-05-08 A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease

Country Status (9)

Country Link
KR (1) KR101016927B1 (en)
CN (1) CN1655793A (en)
AR (1) AR040121A1 (en)
CA (1) CA2426492C (en)
EA (1) EA007632B1 (en)
IS (1) IS7558A (en)
PE (1) PE20040623A1 (en)
UA (1) UA82480C2 (en)
ZA (1) ZA200409147B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105294450A (en) * 2014-05-29 2016-02-03 广州喜鹊医药有限公司 Amantadine nitrate compound with neuroprotective effect, and preparation therefor and medical application thereof

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA107653U (en) 2012-10-01 2016-06-24 Общєство С Огранічєнной Отвєтствєнностью "Валєнта-Інтєллєкт" COMPOSITION OF MEDICINAL PRODUCTS FOR TREATMENT AND PREVENTION OF BEHAVIORAL, MENTAL, AND COGNITIVE DISORDERS
WO2018062941A1 (en) * 2016-09-30 2018-04-05 주식회사 바이오파마티스 Pharmaceutical composition for preventing or treating dementia and cognitive dysfunction, containing donepezil or pharmaceutically acceptable salt thereof and memantine or pharmaceutically acceptable salt thereof, and preparation method therefor
KR20210072569A (en) 2019-12-09 2021-06-17 주식회사 종근당 Complex formulation comprising donepezil and memantine

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105294450A (en) * 2014-05-29 2016-02-03 广州喜鹊医药有限公司 Amantadine nitrate compound with neuroprotective effect, and preparation therefor and medical application thereof
CN105294450B (en) * 2014-05-29 2024-05-17 广州喜鹊医药有限公司 Amantadine nitrate compound with neuroprotection effect, preparation and medical application thereof

Also Published As

Publication number Publication date
CN1655793A (en) 2005-08-17
UA82480C2 (en) 2008-04-25
EA007632B1 (en) 2006-12-29
AR040121A1 (en) 2005-03-16
PE20040623A1 (en) 2004-09-11
ZA200409147B (en) 2006-06-28
KR101016927B1 (en) 2011-02-28
KR20050024296A (en) 2005-03-10
IS7558A (en) 2004-11-26
EA200401617A1 (en) 2005-06-30
CA2426492C (en) 2006-10-03

Similar Documents

Publication Publication Date Title
PL373903A1 (en) A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease
AU7031500A (en) Therapeutic quinazoline compounds
DE69736441D1 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISEASES
BG107515A (en) Therapeutic combination
EP1562897A4 (en) Phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer s disease
GB0223040D0 (en) Therapeutic compounds
HUP0302955A3 (en) Hmg-coa reductase inhibitors, pharmaceutical compositions containing them and their use for treatment of cholesterol related diseases
MY141661A (en) 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
GB0225475D0 (en) Therapeutic agents
EP1201268A3 (en) Combinations of D4 dopamine receptor antagonists with acetylcholine esterase inhibitors
HUP0400732A2 (en) Pharmaceutically active uridine esters
AU3366297A (en) Polymorphic compounds
HUP0202862A2 (en) Pharmaceutical composition containing novel combination of loteprednol and antihistamines
AU2002248319A1 (en) Pharmaceutical composition for the prevention and treatment of scar tissue
AU3173301A (en) Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity
HK1029937A1 (en) Use of phanquinone for the treatment of alzheimer s disease.
CA2282279A1 (en) Atropisomers of 3-heteroaryl-4(3h)-quinazolinones for the treatment of neurodegenerative and cns-trauma related conditions
GB9907571D0 (en) Compounds
CA2426492A1 (en) A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease
UA66932C2 (en) Complex of eletriptan and sulphobutylether-beta-cyclodextrin, pharmaceutical composition, method for their manufacture and method for treating migraine
NZ536111A (en) Statin therapy for enhancing cognitive maintenance
WO2004087157A3 (en) Combination of gh secretagogues and pde4 inhibitors for the treatment of alzheimer's disease
WO2006020852A3 (en) Pharmaceutical composition and method for treating neurodegenerative disorders
AU6519596A (en) Use of allylamine derivatives such as terbinafine, in the manufacture of a medicament for the treatment of helicobacter pylori infection of associated diseases
WO2006020850A3 (en) Pharmaceutical composition and method for treating neurodegenerative disorders

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20140508